Amgen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovation since its founding in 1980. With a strong presence in major operational regions including Europe and Asia, Amgen focuses on developing therapies in areas such as oncology, nephrology, and inflammation. Renowned for its pioneering biologic medicines, Amgen's core products include Enbrel, Neulasta, and Prolia, which are distinguished by their ability to target specific disease pathways effectively. The company has achieved significant milestones, including the introduction of the first recombinant human erythropoietin, Epogen, which transformed the treatment of anaemia. As a prominent player in the biotechnology industry, Amgen continues to excel, holding a strong market position and receiving numerous accolades for its commitment to scientific excellence and patient care.
How does Amgen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Amgen's score of 54 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Amgen reported total carbon emissions of approximately 1.8 billion kg CO2e, comprising 147 million kg CO2e from Scope 1, 14 million kg CO2e from Scope 2, and about 1.7 billion kg CO2e from Scope 3 emissions. The company has set ambitious targets to achieve carbon neutrality for its owned and operated facilities (Scopes 1 and 2) by 2027, with a commitment to reduce absolute Scope 1 and 2 greenhouse gas emissions by 55% from a 2019 baseline. Additionally, Amgen aims to source 100% renewable electricity by 2027, up from 29% in 2019, and ensure that 73% of its suppliers by spend have science-based targets by 2027. As of 2023, Amgen achieved 54% of its targeted reductions for Scope 1 and 2 emissions, demonstrating significant progress towards its climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 144,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - | - | 0,000,000,000 |
Amgen's Scope 3 emissions, which increased by 814% last year and increased significantly since 2012, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 37% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Amgen has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.